Stock Events

Stock Events

Zymeworks BC 

$26.68
49
-$0.1-0.37% Tuesday 20:00

Statistics

Day High
27.33
Day Low
26.14
52W High
28.56
52W Low
11.22
Volume
406,625
Avg. Volume
-
Mkt Cap
2B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.68
-0.45
-0.21
0.03
Expected EPS
-0.296835
Actual EPS
N/A

Financials

-160.8%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
152.61MRevenue
-245.39MNet Income

Analyst Ratings

42.13Average Price Target
The highest estimate is 58.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZYME. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes in the biotechnology field, focusing on monoclonal antibodies, a key area of Zymeworks' research and development.
AMGEN
AMGN
Mkt Cap178B
Amgen is a biotech firm that develops innovative human therapeutics, including bi-specific antibodies, directly competing with Zymeworks' platforms.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is involved in the discovery, development, and commercialization of cancer treatments, competing with Zymeworks' oncology focus.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG, through its Genentech subsidiary, works on biologics for cancer, directly competing with Zymeworks in the oncology and antibody engineering space.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company offers a range of biopharmaceutical products, including cancer therapies that compete with Zymeworks' pipeline.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a broad portfolio including oncology products, competing with Zymeworks in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly and Company focuses on oncology and biopharmaceuticals, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. is known for its work in antiviral drugs but also competes in the oncology space, overlapping with Zymeworks' interests.
Novartis
NVS
Mkt Cap279.67B
Novartis AG is a global healthcare company that competes with Zymeworks in the development of innovative cancer therapies.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC is involved in the discovery and development of a wide range of pharmaceutical products, including those for cancer, making it a competitor in the oncology field.

About

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Kenneth H. Galbraith C.A.
Employees
299
Country
United States
ISIN
US98985Y1082

Listings

MU
DE
ZA8.MU
STU
DE
ZA8.STU
F
DE
ZA8.F
XNAS
US
ZYME

0 Comments

Share your thoughts

FAQ

What is Zymeworks BC stock price today?▼
The current price of ZYME is $26.68 USD — it has decreased by -0.37% in the past 24 hours. Watch Zymeworks BC stock price performance more closely on the chart.
What is Zymeworks BC stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zymeworks BC stocks are traded under the ticker ZYME.
Is Zymeworks BC stock price growing?▼
ZYME stock has fallen by -4.13% compared to the previous week, the month change is a +3.25% rise, over the last year Zymeworks BC has showed a +127.26% increase.
What is Zymeworks BC market cap?▼
Today Zymeworks BC has the market capitalization of 2B
When is the next Zymeworks BC earnings date?▼
Zymeworks BC is going to release the next earnings report on May 07, 2026.
What were Zymeworks BC earnings last quarter?▼
ZYME earnings for the last quarter are -0.55 USD per share, whereas the estimation was -0.46 USD resulting in a -19.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Zymeworks BC revenue for the last year?▼
Zymeworks BC revenue for the last year amounts to 152.61M USD.
What is Zymeworks BC net income for the last year?▼
ZYME net income for the last year is -245.39M USD.
How many employees does Zymeworks BC have?▼
As of May 06, 2026, the company has 299 employees.
In which sector is Zymeworks BC located?▼
Zymeworks BC operates in the Health & Wellness sector.
When did Zymeworks BC complete a stock split?▼
Zymeworks BC has not had any recent stock splits.
Where is Zymeworks BC headquartered?▼
Zymeworks BC is headquartered in Middletown, United States.